Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
621-640 of 936 trials

Blood Cancers: AZD0486 Treatment Study

We are investigating whether AZD0486, alone or with other cancer drugs, is safe and effective for adults with certain blood cancers. This includes conditions like chronic lymphocytic leukemia and large B-cell lymphoma.

Mantle Cell LymphomaLarge B-Cell LymphomaChronic Lymphocytic LeukaemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Accelerator-based BNCT for Head and Neck Cancer

We are exploring a new treatment method for patients with head and neck carcinoma. This study aims to see if it can improve outcomes compared to standard therapies.

Head and Neck Cancer>2 yearsSafety phase (I)OncologyOtolaryngology

Breast Cancer Treatment: I-BCT-1 Study

We are exploring how genetic changes in breast tumors can help select the best treatment options for patients. This study includes patients with neoadjuvant and metastatic breast cancer to improve therapy outcomes.

Breast Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Type 1 Diabetes: Verapamil Treatment for Children

We are studying whether oral Verapamil can help preserve insulin production in children recently diagnosed with Type 1 diabetes. The trial also looks at the safety and effectiveness of this treatment in managing blood sugar levels.

Type 1 Diabetes>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsStandard MedicinesDiabetologyEndocrinology

Solid Tumors: Genetically Modified T-Cell Therapy

We are studying a new treatment using modified T-cells from patients to target specific tumor markers in solid tumors. The trial will help us understand its safety and effectiveness, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Recurrent Grade-4 Glioma: Bortezomib and Temozolomide Study

We are studying the safety and effectiveness of combining Bortezomib with Temozolomide for patients with recurrent grade-4 glioma. This research may help improve treatment options for this challenging condition.

Malignant Glioma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

RAY121: Safety Study in Healthy Volunteers

We are testing a new treatment called RAY121 to see how safe it is and how the body reacts to it. This study helps us understand its effects before it is tested in patients.

Healthy Participants>2 yearsSafety phase (I)Neurology

Hepatocellular Carcinoma: 68Ga-PSMA PET Imaging Study

We are evaluating a new imaging method to see if it can better detect recurrence of liver cancer in patients who have been treated before. This study aims to improve monitoring and treatment strategies for these patients.

Liver Cancer1-2 yearsSafety phase (I)Efficacy phase (II)HepatologyOncology

Ovarian Cancer: ZN-c3 and Niraparib Study

We are studying the safety and effectiveness of a new drug, ZN-c3, alone and with niraparib for patients with platinum-resistant ovarian cancer. This trial aims to find better treatment options for those who have limited choices.

Recurrent Ovarian Cancer>2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Imaging: GEH200520 and GEH200521 Injections

We are testing two new injections to see if they are safe and well-tolerated in patients with cancer. This study aims to improve imaging techniques for better cancer diagnosis.

Malignant Solid Tumor>2 yearsSafety phase (I)OncologyOtolaryngology

BI 3776528: Tolerance Study in Healthy Men

We are testing how well different doses of a new medication are tolerated by healthy men. This study aims to gather important safety information for future research.

Healthy VolunteersSafety phase (I)DermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

Ewing Sarcoma: Dinutuximab Beta with Chemotherapy

We are studying a new treatment combining dinutuximab beta with standard chemotherapy for patients with GD2-positive Ewing sarcoma. The goal is to find the best dose and assess how well it works in improving patient outcomes.

Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Myelofibrosis: Roginolisib with Ruxolitinib

We are studying the safety and tolerability of roginolisib combined with ruxolitinib for patients with myelofibrosis who haven't responded to other treatments. The trial also looks at symptom improvement and changes in spleen size.

MyelofibrosisSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Multiple Myeloma: HDP-101 Treatment Study

We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

ALN-F1202: Safety Study in Healthy Adults

We are testing a new treatment called ALN-F1202 to see if it is safe and well-tolerated in healthy adults. This study is important for future research on its use in patients.

Hereditary Angioedema1-2 yearsSafety phase (I)Allergology

Advanced Solid Tumors: BGB-58067 Study

We are investigating a new treatment for patients with advanced solid tumors to see how safe it is and how well it works. This study will help us understand its effects on tumor growth.

Advanced Solid Tumors with MTAP DeletionNon-Small Cell Lung CancerCholangiocarcinoma>2 yearsSafety phase (I)Oncology

Oral Arsenic for Low-Risk Myelodysplastic Syndromes

We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.

Low-Risk Myelodysplastic Syndromes>2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: JNJ-79635322 Treatment Study

We are exploring a new drug combined with existing therapies for patients with multiple myeloma. The goal is to see if this combination improves treatment outcomes.

Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

ImmunoPet Imaging in Solid Cancers: 89Zr-DFO-REGN5054

We are studying a new imaging method for adults with solid cancers who are being treated with Cemiplimab. This research aims to understand how effectively this imaging can track treatment progress.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology